Though a few early studies identified low frequency EP300 mutations in colorectal carcinoma, breast cancer, and gastric cancer, the full spectrum of mutational inactivation of CREBBP and EP300 would not be fully evident until the genomics era. Here, EP300 is linked to breast cancer.